Literature DB >> 28092206

Impact of UK NICE clinical guidelines 168 on referrals to a specialist academic leg ulcer service.

Huw Ob Davies1, Matthew Popplewell1, Gareth Bate1, Lisa Kelly1, Katy Darvall2, Andrew W Bradbury1.   

Abstract

Background Leg ulcers are a common cause of morbidity and disability and result in significant health and social care expenditure. The UK National Institute for Health and Care Excellence (NICE) Clinical Guideline (CG)168, published in July 2013, sought to improve care of patients with leg ulcers, recommending that patients with a break in the skin below the knee that had not healed within two weeks be referred to a specialist vascular service for diagnosis and management. Aim Determine the impact of CG168 on referrals to a leg ulcer service. Methods Patients referred with leg ulceration during an 18-month period prior to CG168 (January 2012-June 2013) and an 18-month period commencing six months after (January 2014-June 2015) publication of CG168 were compared. Results There was a two-fold increase in referrals (181 patients, 220 legs vs. 385 patients, 453 legs) but no change in mean age, gender or median-duration of ulcer at referral (16.6 vs. 16.2 weeks). Mean-time from referral to specialist appointment increased (4.8 vs. 6 weeks, p = 0.0001), as did legs with superficial venous insufficiency (SVI) (36% vs. 44%, p = 0.05). There was a trend towards more SVI endovenous interventions (32% vs. 39%, p = 0.271) with an increase in endothermal (2 vs. 32 legs, p = 0.001) but no change in sclerotherapy (24 vs. 51 legs) treatments. In both groups, 62% legs had compression. There was a reduction in legs treated conservatively with simple dressings (26% vs. 15%, p = 0.0006). Conclusions Since CG168, there has been a considerable increase in leg ulcer referrals. However, patients are still not referred until ulceration has been present for many months. Although many ulcers are multi-factorial and the mainstay of treatment remains compression, there has been an increase in SVI endovenous intervention. Further efforts are required to persuade community practitioners to refer patients earlier, to educate patients and encourage further investment in chronically underfunded leg ulcer services.

Entities:  

Keywords:  NICE; Varicose veins; guidelines; leg ulcers; ulcer treatment

Mesh:

Year:  2017        PMID: 28092206     DOI: 10.1177/0268355516688357

Source DB:  PubMed          Journal:  Phlebology        ISSN: 0268-3555            Impact factor:   1.740


  3 in total

1.  Study protocol for a multicentre, randomised controlled trial to compare the use of the decellularised dermis allograft in addition to standard care versus standard care alone for the treatment of venous leg ulceration: DAVE trial.

Authors:  Sarah Onida; Francine Heatley; Sarrah Peerbux; Layla Bolton; Tristan Lane; David Epstein; Manjit Gohel; Keith Poskitt; Nicky Cullum; John Norrie; Robert J Lee; Andrew Bradbury; Karen Dhillon; Akila Chandrasekar; Richard Lomas; A H Davies
Journal:  BMJ Open       Date:  2021-04-02       Impact factor: 2.692

2.  The global management of leg ulceration: Pre early venous reflux ablation trial.

Authors:  Francine Heatley; Sarah Onida; Alun H Davies
Journal:  Phlebology       Date:  2020-04-08       Impact factor: 1.740

3.  The management of venous leg ulceration post the EVRA (early venous reflux ablation) ulcer trial: Management of venous ulceration post EVRA.

Authors:  Safa Salim; Francine Heatley; Layla Bolton; Amulya Khatri; Sarah Onida; Alun H Davies
Journal:  Phlebology       Date:  2020-10-26       Impact factor: 1.740

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.